(Current Pharmaceutical Design, 2011) reported that BPC-157 remains stable in human gastric juice for more than 24 hours, which is unusual for a peptide
Jays RETA 10MG in laboratory tests
TB-500: The Mobility Enhancer A synthetic version of thymosin beta-4, TB-500 focuses on enhancing cell migration and reducing fibrosis, which is scar tissue formation
Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Two popular treatments for chronic joint pain are stem cell treatment and platelet-rich plasma (PRP) therapy